Abstract
Recordati's R&D is focused on cardiovascular diseases, anti-infectives,
respiratory, anti-inflammatory, dermatology/gynaecology/urology. This report
provides a full review of the company's activities together with sales
forecasts for key products to 2010.
Recordati was established in 1926 in Milan, Italy and is now listed on the
Italian Stock Exchange. The company employs more than 1,900 people and its
products are sold in about 100 countries.
Recordati markets products in the following fields: Cardiovascular, Central
Nervous System, Gastroenterology/Urology; Respiratory and Anti-infectives. The
company is active in the following areas of research: Cardiovascular; Central
Nervous System, Gastroenterology/Urology and Anti-infectives. However, future
research efforts will focus on fixed combinations in the treatment of
hypertension and the development of therapies for micturition disorders.
Current Growth Drivers
- Zanidip (lercanidipine), an in-house developed calcium channel blocker, is
Recordati's top selling product by a considerable margin, accounting for
around 15 per cent of the company's total revenue. The product continues to
sell well, and Recordati is investing in new combinations and formulations
which should ensure future success and growth.
- Peptazol (pantoprazole), a proton pump inhibitor for the treatment of
ulcers and gastro-oesophageal reflux disease, has demonstrated good
year-on-year growth since its 2002 launch in the Italian market.
Key Late-Phase Products Reaching the Market Place
- Zanipress (lercanidipine+enalapril) is a new fixed combination treatment
for hypertension developed by Recordati. It is currently awaiting approval in
Germany, which will act as the reference member state for approval in the rest
of Europe. Its launch will support the sales of Zanidip and aid Recordati in
making further gains in the European hypertension market.
- Fentanyl is a centrally acting, potent analgesic which is being developed
as a transdermal patch for the treatment of moderate to severe pin. Recordati
has acquired rights to market this product in all the major European markets
and the company hopes its launch will expand its analgesic product portfolio.
Table of Contents
Principal Operating Results
Main Therapeutic Areas
Main R&D Areas
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Growth Drivers
- Key Late-Phase Products Reaching the Market Place
- Key Late-Stage Products
- Key Early-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income, 2005
- Expenditure
- Capital Expenditure
- R&D Expenditure
- R&D Expenditure and Capital Expenditure
- Divisional Performance
- Sales By Business Area
- Sales By Business Area, 2005
- Sales to International Licensees
- Geographic Performance
- Sales By Geographic Area
- Sales By Geographic Area, 2005
- Pharmaceutical Sales By Geographical Area
- Pharmaceutical Sales By Geographical Area
- Pharmaceutical Chemicals Sales By Geographical Area
- Pharmaceutical Chemicals Sales By Geographical Area
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
- Product / R&D Overview
- Key Products
- R&D Strategy
- R&D Pipeline Overview
- Sales Forecasts
- Sales of Major Products (2000A-2010E)
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Sales of Major Products, 2005
- R&D Pipeline
- Cardiovascular - Products
- Major Launched Products
- Zanidip/Zanedip
- Lercanidipine Sales by Geographic Area
- Lercanidipine Sales by Geographic Area, 2005
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents/Licensees
- Sales Forecast
- Zanidip Sales (2000A-2010E)
- Others
- Cardiovascular - R&D
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Central Nervous System - Products
- Major Launched Products
- Elopram
- Sales
- Key Markets/Indications
- Competitor Products
- Generic Competition
- Sales Forecast
- Elopram Sales (2000A-2010E)
- Tora-dol
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Tora-dol Sales (2000A-2010E)
- Central Nervous System - R&D
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
- Gastroenterology / Urology - Products
- Major Launched Products
- Peptazol/Ulcotenal
- Sales
- Key Markets/Indications/Formulations
- Competitor products
- Sales Forecast
- Ulcotenal Sales (2000A-2010E)
- Peptazol Sales (2000A-2010E)
- Others
- Gastroenterology / Urology - R&D
- Gastroenterology / Urology - Summary
- Respiratory - Products
- Exomuc and Hexa
- Exomuc Sales (2000A-2010E)
- Hexa Sales (2000A-2010E)
- Others
- Respiratory - R&D
- Respiratory - Summary
- Anti-infectives - Products
- Major Launched Products
- Isocef
- Sales
- Competitor Products
- Sales Forecast
- Isocef Sales (2000A-2010E)
- Octegra
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Patents
- Sales Forecast
- Octegra Sales (2000A-2010E)
- Anti-infectives - R&D
- Anti-infectives - Summary
- Others - Products
- Others - R&D
- Ciclosporin
- REC 2615
- Stanate
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY AGREEMENTS
- Altana
- Angelini
- Asinex Ltd
- AstraZeneca
- 26th October 1998
- July 2001
- bioMérieux-Pierre Fabre
- Dexcel Pharma Group
- Eurand Pharmaceuticals Ltd
- Forest Laboratories Inc
- Fournier Pharma Inc
- Grupo Uriach
- 4th September 2003
- 14th September 2004
- InfaCare Pharmaceutical Corporation
- Kissei Pharmaceutical Co Ltd
- Kowa Company Ltd
- Labopharm Inc
- Lavipharm Laboratories Inc
- LifeCycle Pharma
- Lundbeck
- Meda AB
- Napp Pharmaceuticals Ltd
- Osmotica Pharmaceutical
- Roche
- Rotta Research Laboratorium SpA
- Zambon Group
- Licensing
- Co-Promotion/Co-Marketing
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
APPENDIX 5 - PRODUCT INDEX
医薬品
その他のカテゴリ
FAQ